EP3237597A1 - Devices for high-throughput aggregation and manipulation of mammalian cells - Google Patents
Devices for high-throughput aggregation and manipulation of mammalian cellsInfo
- Publication number
- EP3237597A1 EP3237597A1 EP14830888.5A EP14830888A EP3237597A1 EP 3237597 A1 EP3237597 A1 EP 3237597A1 EP 14830888 A EP14830888 A EP 14830888A EP 3237597 A1 EP3237597 A1 EP 3237597A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- microwells
- cell
- groups
- cells
- microwell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002776 aggregation Effects 0.000 title description 17
- 238000004220 aggregation Methods 0.000 title description 17
- 210000004962 mammalian cell Anatomy 0.000 title description 2
- 230000004931 aggregating effect Effects 0.000 claims abstract description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 50
- 239000000017 hydrogel Substances 0.000 claims description 44
- -1 polyethylene copolymers Polymers 0.000 claims description 25
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 125000000524 functional group Chemical group 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 230000000269 nucleophilic effect Effects 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 10
- 229920000936 Agarose Polymers 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 108010082117 matrigel Proteins 0.000 claims description 6
- 229920002635 polyurethane Polymers 0.000 claims description 6
- 239000004814 polyurethane Substances 0.000 claims description 6
- 239000002243 precursor Substances 0.000 claims description 6
- 150000003573 thiols Chemical class 0.000 claims description 6
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 102000008186 Collagen Human genes 0.000 claims description 5
- 229940072056 alginate Drugs 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 5
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 102000015636 Oligopeptides Human genes 0.000 claims description 4
- 108010038807 Oligopeptides Proteins 0.000 claims description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 4
- 239000012620 biological material Substances 0.000 claims description 4
- 238000004132 cross linking Methods 0.000 claims description 4
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical class C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 claims description 2
- 150000003923 2,5-pyrrolediones Chemical class 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 2
- 229920000856 Amylose Polymers 0.000 claims description 2
- 101100291399 Arabidopsis thaliana MLO7 gene Proteins 0.000 claims description 2
- 102000000584 Calmodulin Human genes 0.000 claims description 2
- 108010041952 Calmodulin Proteins 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 2
- 102000009123 Fibrin Human genes 0.000 claims description 2
- 108010073385 Fibrin Proteins 0.000 claims description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 2
- 108010090804 Streptavidin Proteins 0.000 claims description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims description 2
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 229950003499 fibrin Drugs 0.000 claims description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims description 2
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical class CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 108010087904 neutravidin Proteins 0.000 claims description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 229920000570 polyether Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 150000004053 quinones Chemical class 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 229920001059 synthetic polymer Polymers 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims 1
- 229940099552 hyaluronan Drugs 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 138
- 239000004205 dimethyl polysiloxane Substances 0.000 description 34
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 34
- 238000003491 array Methods 0.000 description 30
- 239000000758 substrate Substances 0.000 description 24
- 238000000034 method Methods 0.000 description 23
- 239000000463 material Substances 0.000 description 19
- 239000002609 medium Substances 0.000 description 15
- 230000012010 growth Effects 0.000 description 14
- 238000004113 cell culture Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 229920001486 SU-8 photoresist Polymers 0.000 description 8
- 230000007774 longterm Effects 0.000 description 8
- 238000009826 distribution Methods 0.000 description 7
- 210000002304 esc Anatomy 0.000 description 7
- 238000010899 nucleation Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000005266 casting Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000012388 gravitational sedimentation Methods 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000000935 solvent evaporation Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000000151 deposition Methods 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000002236 cellular spheroid Anatomy 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000007667 floating Methods 0.000 description 3
- 238000007306 functionalization reaction Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000011031 large-scale manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000000820 replica moulding Methods 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 102000046949 human MSC Human genes 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000011344 liquid material Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000005499 meniscus Effects 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229920002120 photoresistant polymer Polymers 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 238000012605 2D cell culture Methods 0.000 description 1
- 238000012604 3D cell culture Methods 0.000 description 1
- 238000009623 Bosch process Methods 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000009815 adipogenic differentiation Effects 0.000 description 1
- 210000000677 aggregate cell Anatomy 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000007641 inkjet printing Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000001053 micromoulding Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002444 silanisation Methods 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013520 translational research Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
- B01L3/5085—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
- C12M1/26—Inoculator or sampler
- C12M1/32—Inoculator or sampler multiple field or continuous type
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/12—Well or multiwell plates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/16—Microfluidic devices; Capillary tubes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/20—Material Coatings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
- C12M3/06—Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/02—Adapting objects or devices to another
- B01L2200/026—Fluid interfacing between devices or objects, e.g. connectors, inlet details
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
- B01L2200/0668—Trapping microscopic beads
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0829—Multi-well plates; Microtitration plates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0848—Specific forms of parts of containers
- B01L2300/0851—Bottom walls
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0893—Geometry, shape and general structure having a very large number of wells, microfabricated wells
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/16—Surface properties and coatings
- B01L2300/161—Control and use of surface tension forces, e.g. hydrophobic, hydrophilic
- B01L2300/165—Specific details about hydrophobic, oleophobic surfaces
Definitions
- the present application relates to devices for high-throughput aggregation of cells and their long-term culture as well as their manipulation within the device.
- Such cell aggregates are used in basic biology, especially developmental and cancer biology, regenerative medicine and pharmaceutical screenings.
- the present invention also concerns methods for the fabrication of such devices.
- Tissues self-organize as complex three-dimensional entities of specialized cells, adjacent support cells, extra-cellular matrix components and other structural and dimensional elements that cross talk continuously to ensure and maintain function (Li et al. 2005).
- This multicomponent microenvironment termed niche, has been minimally simplified in classical two-dimensional cell culture systems that serve as standardized platforms for basic research ranging from developmental biology studying the differentiation of cell types of interest to pharmacological screenings of, for example, tumorigenic cells.
- results from such two-dimensional assays critically lack the translational aspect back to the three-dimensional in vivo environment (Griffith etal. 2006).
- experimental designs have been strongly shifting during the past decade towards the implementation of more relevant 3D models, such as cell aggregate cultures (Abbott 2003, Zhang 2004, Pampaloni et al. 2007).
- the AggrewellTM800 system indeed harbours microwells with a flat bottom plane, representing a final structure of pyramidal frustums, which partially, if not fully, defeats the purpose of the initial invention of providing a cell collection device where all cells are collected in a central point of summed gravitational forces. Furthermore the system generally exhibits multiple limitations, which render its application for long-term culture of cell spheroids difficult. Larger sized EBs formed in AggreWellTM plates by either high initial cell seeding density or cell aggregation followed by spheroid growth for longer than 24h tend to form cone-like structures reflecting the architecture of the AggreWellTM microwell.
- Constraining cells in non-natural conformations has unknown effects on their biological function and it is currently suggested that shape of the culture substrate can induce uncontrolled and unspecific lineage commitment (Shiku et al. 2013).
- AggreWellTM plates are limited to optimal medium exchange during culture as handling steps such as pipetting disturbs constraint of the spheroids within the microwells due to large openings towards the plane exposed to the bulk medium.
- AggreWellTM plates are sold as microwell arrays casted in polydimethylsiloxane (PDMS), a silicone elastomer that does not allow nutrient diffusion, which affects growth and survival of cells on the side exposed to PDMS surfaces (Lee etal. 2004). Furthermore, it is well known that PDMS is prone to biomolecule adsorption on its surface (Toepke et al. 2006), a factor risking to bias final results of cell signalling and drug screening experiments.
- PDMS polydimethylsiloxane
- KR 20130013537 A relates to a manufacturing method of microstructures and a method for cell collecting using said microstructures.
- the pitch (well-spacing) is identical to the diameter of the wells
- the material used is limited to PDMS
- An aim of the present invention is to improve the known cell aggregate systems.
- a further aim of the present invention is to propose a system that allows a better tailoring to the need of the user with regards to through-put, size and geometry and interfaces with in situ manipulation techniques.
- a further aim is to propose a system that is user-friendly, reproducible and reliable.
- a novel family of cell aggregate systems is proposed according to the present invention that will also enable the long-term culture of the formed cellular spheroids within the same culture format.
- a 3D culture system is composed of an array of high-aspect ratio round-bottom as well as U-bottom shaped microwells with low pitch sizes and high side walls that can be reproduced in various materials not limited to PDMS and other polymeric materials such as plastics, but more importantly hydrogels such as those based on synthetic hydrophilic polymers, preferably poly(ethylene glycol) (PEG), or naturally derived components such as Matrigel, agarose, gelatin or collagens.
- PEG poly(ethylene glycol)
- the present invention takes advantage of solvent evaporation of dilute polymer solutions to create round-shaped as well as U- shaped structures.
- the round bottom shape is included in the U-bottom shape.
- Round bottom microwells refer to U-bottom shaped microwells wherein the height of the microwell is equal to the radius of the spherical bottom. Henceforth only the term U-bottom or U-shaped will be used.
- the formed U-bottom microwell structures are then molded in the substrate of interest.
- the advantages of using especially PEG-based hydrogels as substrate materials lie in the high permeability of nutrients, optimal and tailor-made bioactivity while ensuring otherwise biological inertness (Lutolf et al. 2005).
- PEG-based substrates will permit the selective conjugation of desired biomolecules to the bottom of the depicted microwells, allowing the study of also non-soluble factors on cellular behaviour and development within aggregates.
- spheroids can be embedded below the surface plane of the culture substrate to minimize disturbance through handling procedures such as movement or medium changes.
- Minimal pitch sizes in the range of few cell diameters between the wells are sufficient to inhibit single cells to rest on these borders, a process that can disturb equal cell distribution in each well and that can exhibit uncontrolled signalling.
- the integration of microfluidic networks in close proximity to the microwell plane for the local and timed delivery of molecules of interest allows the selective manipulation of the formed aggregates during long-term culture. Additionally, this platform can be applied for complete encapsulation of formed aggregates through sandwich casting of a second layer of substrate atop the formed spheroids, which will allow planar localization and drastically facilitate automated imaging during culture.
- the present invention provides a method for generating cell aggregates comprised of one or multiple cell types, through:
- the present invention proposes a novel all-in-one 2D and 3D cell culture platform that offers high-throughput formation of cellular spheroids while allowing their long-term culture without need to change culture format while also enabling manipulation of the formed aggregates by local delivery of desired bioactive molecules for functional studies.
- the invention concerns a device for aggregating cells, said device comprising at least one cavity wherein said cavity comprises a plurality of microwells for receiving at least one cell, wherein each said well comprises a vertical sidewall and a curved bottom.
- the device comprises a plurality of cavities, each said cavity comprising a plurality of microwells.
- the diameter (d), the height (h) and the interwell distance (pitch, p) of the microwells are uncoupled and can be varied independently of each other.
- the microwells have an opening diameter of ⁇ to 3mm.
- the microwells have heights (h) of ⁇ to 3mm. In one embodiment, the microwells have cavities of different sizes or shapes.
- the spacing (pitch size) between the microwells is minimal such that cells falling within the area of the well will fall into a microwell and participate in aggregate formation.
- the spacing between the microwells is in the range of ⁇ to ⁇ .
- the device comprises a microfluidic network with channels.
- the network of channels is beneath the plane of the microwells.
- the network of channels is aligned with the microwells.
- the distance between the network of channels and the bottom of the microwells is less than 500 ⁇ .
- said microwells are made in a hydrogel layer.
- the hydrogel layer is based synthetic hydrophilic polymers, or naturally derived components or hybrids of synthetic polymers and naturally derived components.
- the synthetic hydrophilic polymer is selected from the group comprising poly(ethylene glycol), polyaliphatic polyurethanes, polyether polyurethanes, polyester polyurethanes, polyethylene copolymers, polyamides, polyvinyl alcohols, poly(ethylene oxide), polypropylene oxide, polyethylene glycol, polypropylene glycol, polytetramethylene oxide, polyvinyl pyrrolidone, polyacrylamide, polyfhydroxy ethyl acrylate), poly (hydroxy ethyl methacrylate), or mixtures thereof.
- the hydrogel is prepared by mixing and cross-linking of at least two precursor components using a chemical reaction, wherein the first precursor component comprises n nucleophilic groups and the second precursor component comprises m electrophilic groups, wherein n and m are at least two and the sum n+m is at least five, and wherein the crosslinking is preferably conducted between
- a multi-arm-PEG macromer preferably a four-arm-PEG macromer, end- functionalized with nucleophilic, prefera-bly thiol-groups, with
- multi-arm-PEG macromer preferably an eight-arm-PEG macromer, end-functionalized with electrophilic, prefer-ably vinylsulfone-groups at appropriate concentrations and conditions such as to allow for the crosslinked hydrogel layer to exhibit a shear modulus between 0.1 and 100 kPa.
- the hydrogel comprises an excess of free functional groups, preferably nucleophilic groups, more preferably chosen from the group comprising amines and thiols, and - in addition or alternatively - electrophilic groups, preferably chosen from the group comprising acrylates, methacrylates, acyl-amides, methacrylamides, acylonitiriles, quinones, vinyl-sulfones, maleimides and their derivates.
- free functional groups preferably nucleophilic groups, more preferably chosen from the group comprising amines and thiols, and - in addition or alternatively - electrophilic groups, preferably chosen from the group comprising acrylates, methacrylates, acyl-amides, methacrylamides, acylonitiriles, quinones, vinyl-sulfones, maleimides and their derivates.
- the microwells may be functionalized with one or more types of bio-molecules.
- the biomolecules are proteins, oligopeptides, oligonucleotides, or sugars.
- the proteins or peptides are ECM-derived or ECM-mimetic and attached to the nucleophilic or electrophilic groups, preferably the thiol groups of the PEG-based layer, using a heterobifunctional linker, wherein one functional group of the linker is reactive to the functional groups attached to termini of the polymer chains and the other functional group of the linker selected from the group comprising succinimidyl active ester such as N- hydroxysuccinimide (NHS), succinimidyl alpha-methylbutanoate, succinimidyl propionate, aldehyde, thiol, thiol-selective group comprising acrylate, maleimide or vinylsulfone, pyridylthioesters and pyridyldisulfide, is capable of nonspecifically tethering to the biomolecule of interest via its amine groups.
- the biomolecules are tagged such as to be tethered to the hydrogel surface
- the tagged biomolecules have tags to enable binding to targets chosen from the group comprising ProteinA, ProteinG, ProteinA/G, Streptavidin, NeutrAvidin, NTA, antibodies, S-fragment of RNaseA, calmodulin, cellulose, chitin, glutathione, amylose, or functionalized oligopeptides and oligonucleotides having nucleophilic or electrophilic functional groups that can react with the functional groups on the hydrogel network.
- targets chosen from the group comprising ProteinA, ProteinG, ProteinA/G, Streptavidin, NeutrAvidin, NTA, antibodies, S-fragment of RNaseA, calmodulin, cellulose, chitin, glutathione, amylose, or functionalized oligopeptides and oligonucleotides having nucleophilic or electrophilic functional groups that can react with the functional groups on the hydrogel network.
- the naturally derived components are selected from the group comprising polysaccharides, gelatinous proteins, and ECM components such as agarose, alginate, chitosan, dextran, gelatin, laminins, collagens, hjsluromin, fibrin or mixtures thereof or are selected from the group of complex tissue derived matrices comprising Matrigel, Myogel and Cartigel.
- ECM components such as agarose, alginate, chitosan, dextran, gelatin, laminins, collagens, hjsluromin, fibrin or mixtures thereof or are selected from the group of complex tissue derived matrices comprising Matrigel, Myogel and Cartigel.
- the main strength of the present invention is the decoupling of the microwell diameter, height and the inter-well distance that grants a total freedom in array geometry.
- the proposed U-bottom shaped microwell arrays are preferably formed with soft and highly hydrated substrates such as hydrogels rather than elastomers, such as PDMS, to mimic as close as possible the physiological environment of cells. It was demonstrated that single cell survival on the proposed substrate was significantly higher than PDMS-based platforms (such as disclosed in the KR prior art application cited above) and that cell aggregate growth was catalyzed on the proposed substrate.
- hydrogel-based microwell array platform it was demonstrated that one could link the ability to aggregate cells in a high-throughput fashion and the potential to provide these cells a three-dimensional environment by encapsulating them in an upper layer of hydrogel.
- the platform is made of hydrogel, one could show the possibility to integrate microfluidic networks into the platform.
- hydrogel As an additional advantage of the use of hydrogel, one could demonstrate the possibility to chemically crosslink biofunctional ligand onto the microwells surface enabling the assessment of the influence of tethered cues on the cultured aggregates.
- the integration of three-dimensional culture, microfluidic networks and microwell patterning and biofunctionalization into the same platform opens a totally new physico-chemical and spatio-temporal space for high-resolution screenings of 3D microtissues.
- the platform could be used with any cell type, and more specifically, with non spheroid-forming cell types such as MDA-MB231, human breast cancer cells, that formed aggregates after two to three days and kept tightly aggregated for at least five days.
- non spheroid-forming cell types such as MDA-MB231, human breast cancer cells, that formed aggregates after two to three days and kept tightly aggregated for at least five days.
- the present invention presents the unique opportunity to enable "controllable" cell co-cultures. Co-cultures are possible by either initially seeding multiple cell types simultaneously or through the addition of other cell types to an ongoing spheroid culture. Additionally, more than two cell types can be added at any given time during the culture to allow for the systematic study of self-organization, migration and cell redistribution.
- the presented technology is a highly versatile and innovative multidimensional screening platform for high-resolution screenings in space and in time.
- the present approach consists in biological application specific-based platform development unlike most of the aforementioned platforms. It is believed that these kind of fully integrated technologies will support fundamental biology advances as well as strongly catalyze translational research to clinics.
- Figures 1A to ID illustrates the principle of the present invention
- Figure 2 illustrates a microwell array three-dimensional geometry (inverted) according to the present invention
- Figure 3 illustrates a microwell array top view geometry
- Figure 4 illustrates an overall view of an U-bottom microwell array
- Figure 5 illustrates a conceptual description of the U-bottom well fabrication process
- Figures 6A to 6C illustrate a theoretical and actual view of the geometry of a U- bottom microwell
- Figure 7 illustrates a conceptual description of hydrogel casting
- FIGS 8A to 8D illustrate different U-shaped microwell sizes
- FIGS 9A to 9D illustrate U-shaped microwells reproduced in materials with different stiffness
- Figure 10 illustrates examples of U-shaped microwells produced in a variety of materials as indicated;
- Figure 11 illustrates examples of small sizes microwells;
- FIGS 12 A-N illustrate limitations of the standard AggreWellTM platform
- Figures 13 A-G illustrate an example of varying cell density
- Figures 14 A-G illustrate an example of aggregate growth, size distribution and pluripotency maintenance
- Figure 15 illustrates an example of aggregation potential of varying cell types as indicated
- Figure 16 illustrates example of aggregation potential of non-sphere forming cell types as indicated;
- Figures 17 A-C illustrate an example of three-dimensional culture format;
- Figures 18 A-F and enlargement 18 G illustrate an example of U-bottom microwell arrays with microfluidic integration
- Figure 19 illustrates an example of a bio-functionalization of the microwell bottom
- Figure 20 illustrates examples of microwells in different shapes (top views and sections views).
- Figures 1A to ID illustrate the principle of the present invention.
- a plate 1 is provided with a series of wells 2.
- Typical sizes of said commercially available wells 2 are about 6.4-34.8mm in diameter and 1.76cm in depth holding total liquid volumes of 0.36-16.8mL corresponding to working volumes of 0.1-0.2mL to 1.9-2.9mL.
- Figure IB shows a side cut view of the plate 1 of figure 1A with its wells 2. One sees in this figure IB a set of microwells 3 which are placed at the bottom of each well 2 which forms one feature of the present invention.
- microwells 3 are illustrated in more detail in figure 1C which is an enlarged view taken from a well 2 of figure IB.
- the present invention in an embodiment proposes to provide a set of microwells 3 in a set of larger wells 2 of a plate 1.
- Figure 2 shows a microwell 3 array 4 with a three-dimensional geometry (inverted).
- the three dimensional geometry of the microwell array 4 is shown inverted.
- Figure 3 illustrates an example of a microwell array 4 in top view geometry. The theoretical top view of these arrays 4 is shown here.
- the microwells 3 have been organized in order to maximize the density of wells for a given area of the array 4. Also, this organization of microwells 3 allows to minimize the inter-well distance, thus, preventing cells to grow in-between microwells 3.
- the distances d, h and p which are defined in figure 1C, can be chosen independently with the fabrication techniques that are described in the present application.
- the size of d and h can range from ⁇ to 3000 ⁇ (3mm); the size range of p can be freely chosen.
- h should be always larger than or equal to d and p should be as small as possible, much smaller than d (p «d) and typically in the range of 1 ⁇ -100 ⁇ . If needed, p larger than ⁇ can be realized without restrictions.
- Figure ID illustrates the percentage of cell capturing area (area covered by microwells) as a function of the pitch size to well diameter ratio. At a ratio of 10:1, the microwells already cover 74.95% of the total area.
- FIG 4 illustrates an overall view of a U-bottom microwell 3 array.
- An array with a bottom diameter of 8mm is cast in a well 2 of a 12-well plate 1 (see figure 1A).
- Brightfield and fluorescent representation (small insert, left) of an area of the array 4 with 72 microwells 3 containing clusters of 0ct4::GFP ESCs are shown.
- the size of the aggregates is monodisperse and the pluripotency marker 0ct4 is displayed in each cell cluster. This aggregate homogeneity illustrates the strong reproducibility of the U-bottom microwell 3 platform.
- the following table 1 gives examples of well plates 1 (see figure 1A) with different numbers of wells 2 per plate (6, 12, 24, 48 and 96), the well bottom area and the microwells 3 diameter depending on the number of microwells 3 per well 2.
- One of the advantages of the present invention is that it allows an easy refilling of the medium in the microwells 3. Indeed, rather than refill each of said microwells 3 individually, which is, in addition, impossible below a given microwell size. With the present invention, it is possible to act at the level of the wells 2 which are larger than the microwells 3 and thus easier to refill.
- FIG. 5 illustrates a conceptual representation of a U-bottom microwell 3 fabrication process according to the present invention.
- U-bottom microwells 3 are formed through defined volume deposition of dilute liquid materials, for example polymers, such as the epoxy-based photoresist SU-8, to allow spherical bottom shape formation through solvent evaporation.
- dilute liquid materials for example polymers, such as the epoxy-based photoresist SU-8
- the deposited material condenses and wets the microwell 3 wall to form an inverted half spherical bottom shape 5 at the bottom of the wells through surface tension forces.
- the structures can be used for replica moulding to fabricate the microwell 3 arrays 4.
- Figure 6A illustrates a theoretical description of the final geometry of a microwell post-evaporation, as discussed above in relation to figure 5.
- a perspective illustration of a single Si well 3 with inverted SU-8 cap 5 at the bottom of the well is shown including a cross-section along the center, r depicts the radius of the inverted cap, that equals the radius of the pre-etched well, hi relates to the depth of the well equal to the depth pre-etched in Si.
- h2 relates to the total height of printed SU-8 before solvent evaporation, approximating the radius of the pre- etched well (figure 6B).
- An example of a microwell 3 with SU-8 deposition to form a U-shaped well bottom (bottom left) or without (bottom right) replica-molded into PEG hydrogel is given in the image of figure 6C.
- Figure 7 illustrates an example of a conceptual description of PDMS & hydrogel casting of a plate 1 according to the present invention.
- the U-bottom structures are replica-molded into PDMS.
- the formed PDMS U-bottom microwell negative is then used to cast any desired material onto coverslips or directly at the bottom of wells 2 of tissue culture plates 1.
- Coverslips, where employed, may be fixed in any suitable manner in the wells 2, for example through biocompatible adhesive thin films, such as thin layers of PEG hydrogel.
- Figures 8A-8D illustrates examples of different U-shaped microwell sizes.
- PEG hydrogel G' ⁇ 12.5kPa
- different combinations of the varying parameters, (d, distance, h, height and p, pitch were achieved.
- Confocal images (orthogonal views) of microwells 3 of ⁇ , 250 ⁇ , 400 ⁇ and 1.25mm diameter are represented (A-D). The exact design of these three different samples is the following:
- the microwell 3 has a diameter of ⁇ , a height of 200 ⁇ and an interwell distance of 40 ⁇ .
- the microwell 3 has a diameter of 250 ⁇ , a height of 400 ⁇ and an interwell distance of 40 ⁇ .
- the microwell 3 has a diameter of 400 ⁇ , a height of 400 ⁇ and an interwell distance of 40 ⁇ .
- the microwell 3 has a diameter of 1.25mm, a height of 1mm and an interwell distance of 40 ⁇ .
- FIG. 9A to 9D illustrates U-bottom microwells in different stiffness.
- PEG hydrogels with varying polymer content w/v, 1.25%, 2.5%, 5%, 10%, as indicated in the drawings
- different absolute stiffnesses were demonstrated to be moldable as U-bottom microwell arrays.
- the U-bottom microwell structures of the present invention were easily imprinted in hydrogels having a stiffness of 150 Pa (G'), figure 9A, to approx.. 30 kPa (G'), figure 9D. This wide coverage is crucial to address biological questions relating to cell aggregate interactions with substrates of varying rigidity.
- Figure 10 illustrates the variety of materials that may be used as indicated in the drawings. From the PDMS negative mold, diverse materials were imprinted with the above-described pattern. PDMS can be replica molded to give rise to U-bottom microwell arrays in PDMS. Preferably the U-bottom microwell arrays are reproduced in soft biocompatible polymers: standard synthetic hydrogels such as polyethylene glycol (PEG) were demonstrated to be moldable as well as natural hydrogels, such as agarose, alginate, gelatin, matrigel and collagens. Of course, other equivalent materials may be used.
- PEG polyethylene glycol
- FIG 11 illustrates an embodiment of small sizes wells.
- Microwells 3 of sizes comprised between 10 and 50 ⁇ wells were moulded in 12.5kPa PEG hydrogel to create a single cell culture platform. Single cells were successfully seeded in separate well.
- Figure 12 (A) to (N) shows the limitations of the standard AggreWellTM platform.
- Brightfield representations of harvested 0ct4::GFP ESCs aggregates (i.e. 500, 1000, 2000 and 3000 cells per microwell) after 24h of culture in 400 ⁇ diameter U-bottom microwells (A-D) as well as 400 ⁇ dimensioned AggrewellsTM (E-H).
- A-D 400 ⁇ diameter U-bottom microwells
- E-H 400 ⁇ dimensioned AggrewellsTM
- Several limitations of the AggreWellTM platform were observed. As already suggested, (Shiku et al. 2013) cells aggregating in pyramidal shaped microwells adopt a pyramidal shape (top). This can be seen with many different cell-seeding densities, for example 500, 1000, 2000 and 3000 cells per microwells (arrows).
- cell aggregates such as 0ct4::GFP ESCs (M) and NIH3T3 fibroblasts (N) aggregates, seeded onto AggreWellTM surface (PDMS surface) were observed to crawl along the microwells walls.
- M 0ct4::GFP ESCs
- N NIH3T3 fibroblasts
- PDMS surface AggreWellTM surface
- Figure 13 (A) to (G) illustrates examples of measured varying cell density.
- mouse 0ct4::GFP ESCs three different cell densities
- the microwell arrays according to the present invention are a potent tool to assess heterogeneity of stem cell populations at the single cell level, such as their varying clonal expansion potential.
- Figure 14 (A) to (G) illustrates aggregate growth, size distribution and pluripotency maintenance.
- Aggregate growth of mouse 0ct4::GFP ESCs was assessed for 5 days in the U-bottom microwell platform according to the present invention (RBW PEG) in comparison to the AggreWellTM platform (AW PDMS) (A).
- RBW PEG U-bottom microwell platform
- AW PDMS AggreWellTM platform
- the size distribution of the aggregates was assessed at day 5.
- the U-bottom microwell platform according to the present invention (C) shows a higher monodispersity of the aggregates' size compared to AggreWellsTM (B).
- Figure 15 illustrates an example of aggregation potential of varying cell types as indicated in the figure.
- Various cell types were seeded onto the U-bottom microwell arrays according to the present invention.
- Brightfield representations of C2C12, HEK293T, NIH3T3 fibroblasts, NMuMG/E9 and human MSCs PT-2501 are shown.
- the different cell types successfully formed aggregates and could be maintained for 5 days. Also they were all successfully harvested and kept clustered (data shown for hMSCs PT-2501 only, as a representative example).
- This high versatility of use demonstrates the strong potential of the microwells platform according to the present invention.
- Figure 16 illustrates an example for the aggregation potential of non-sphere forming cell types as indicated in the figure.
- Non-sphere forming cells were seeded onto U-bottom microwell arrays according to the present invention.
- Brightfield representations at different culture times of MCF-7, MDA-MB231 and OP9 as well as the corresponding harvested aggregates at day 5 are shown.
- the different cell types successfully formed aggregates and could be maintained for 5 days. Also, all three cell types were successfully harvested and kept clustered.
- Figure 17 (A) to (C) illustrates an example of three-dimensional culture format.
- FIG. 1 Perspective illustration of 3D encapsulated aggregates by sandwich casting of a second layer 6 of substrate, showing the potential of the technology according to the present invention to combine the localization of the aggregates in one single z-plane to enable encapsulated three-dimensional cultures.
- Figures 18 (A) to (F) and 18G illustrate a U-bottom microwell array according to the present invention with microfluidic integration through perfusable micrometer-scale channels.
- the network 5, 6 may be placed beneath the plane of the microwells 3 and aligned with it or not.
- Figure 19 illustrates an example of functionalization of the microwell bottom. Confocal representation of a U-bottom shaped microwell 3 (270 ⁇ in diameter, 400 ⁇ in height, 40 ⁇ pitch. The bottom of the microwell3 is functionalized with a model protein, here BSA..
- Figure 20 illustrates examples of microwells 3 according the present invention of different shapes. Schematic representation of microwells 3 having multiple geometrical shapes. Any shape, such as triangles, squares, toroids, and fully irregular structures can be used to produce U-bottom microwells with the above- discussed technique. These can be used for multiple applications; especially it can be a powerful tool for assessing the impact of the culture substrate geometry on cellular functions.
- Figures 20 illustrates top views and section views along A-A and B-B. Fabrication/ Material and Methods
- U-bottom microwell array fabrication Using a Si Bosch process, flat-bottom microwells (here, cylindrical) of desired dimensions were etched into a silicon substrate. Then, a precise volume of a dilute liquid material, for example polymers, such as the positive photoresist SU-8, was added into these wells using inkjet printing.
- a dilute liquid material for example polymers, such as the positive photoresist SU-8
- Other deposition techniques can include, automated liquid dispensing, such as robotic liquid handling workstations, manual dispensing, such as pipetting, or any other type of deposition method.
- the material forms an evaporation meniscus, and creates a spherical bottom to form the U-shaped structures (see figures 5 and 6).
- the material is finally solidified and used as a pattern for PDMS replica molding, which was then used as a molding pattern for the final substrate (e.g hydrogel). This replica molding process allows the replication of the silicon substrate geometry into the desired final substrate (see figure 7).
- hydrogel i.e. synthetic hydrogels as well as natural or naturally derived hydrogels
- PEG polymer such as PDMS, SU-8, etc.
- plastics such PMMA, PLA, PPA, PP, PE and so on, ceramics, metals, alloys, minerals, non metallic mineral, and glass.
- mESCs human embryonic stem cells
- DMEM Dulbecco's Modified Eagle Medium
- LIF leukemia inhibitory factor
- FBS ESC screened fetal bovine serum
- ES cell medium 0.1 mM
- Human mesenchymal stem cells hMSCs, PT-2501, Lonza
- OP9 murine stromal cells were routinely maintained in alpha-MEM supplemented with 10% FCS (Hyclone, batch AUA33984) and Ing/mL human FGF-2 (Peprotech).
- NIH3T3 fibroblasts MCF-7 human breast cancer cells, MDA-MB231 human breast cancer cells, C2C12 mouse myoblast cells, NMuMG E9 mouse breast cancer cells and human embryonic kidney (HEK) 293 cells were routinely maintained in DMEM supplemented with 10% fetal bovine serum (FBS), HEPES (10 mM) and sodium pyruvate (1 mM).
- FBS fetal bovine serum
- HEPES 10 mM
- sodium pyruvate 1 mM
- a cell suspension with a density of interest was prepared (i.e. 3xl0 5 cells/mL, 6xl0 4 cells/mL, and 1000 cells/mL for achieving 500 cells/microwell, 100 cells/microwell and 1 cell/microwell, respectively) in the cell-type specific media.
- the U-bottom shaped microwell arrays were casted at the well bottom of 24-well plates and 2mL of the prepared cell solution was added in the well. Cells settled down by gravitational sedimentation.
- the cells were cultured for 5 days and the respective media was changed everyday.
- U-bottom microwells 3 arrays 4 of different sizes were molded into a variety of cell culture compatible substrates, including PDMS, PEG, agarose, gelatin, alginate and matrigel.
- the U-bottom microwells 3 arrays 4 were molded into PEG with polymer contents (w/v) ranging between 2.5% to 10% (figure 9).
- the lowest PEG stiffness castable was determined to be 150 Pa, equivalent to 2.5% PEG polymer content (as determined by rheology), below which architecture of the microwells 3 structure is no longer entirely guaranteed.
- the U-bottom microwells 3 can be efficiently reproduced in the aforementionned materials demonstrated by the preserved architecture (see figure 10).
- U-bottom microwells 3 arrays 4 in 5% (w/v) PEG hydrogels were used to aggregate and culture 0ct4::eGFP transgenic mouse ES cells.
- Initial aggregate size can be controlled by tuning the cell-seeding density. Densities of single cells, 100 cells per EB and 500 cells per EB were targeted. Aggregate sizes 24h after seeding were determined and compared (see figure 13A-C). Single cells, 100 cells, 500 cells lead to EBs of 10-40 ⁇ , 90-130 ⁇ and 110-170 ⁇ in diameter.
- Aggregate growth was quantified over the time course of five days from EBs of a starting density of 500 cells (see figure 14D) between U-bottom microwells with a diameter of 400 ⁇ in PEG (RBW PEG) and AggreWellTM400 (AW PDMS).
- the growth rate increases significantly (p ⁇ 0.0001) after 48h for RBW PEG (see figure 14A)
- culturing 500 0ct4::eGFP cells per microwell leads to larger and more monodisperse final aggregate populations on RBW PEG compared to AW PDMS (see figure 14C-D).
- U-bottom microwell arrays were molded in 5% (w/v) PEG hydrogels. Aggregates of various cell types were formed within these microwell arrays at a given starting density. C2C12, HEK293T, NIH 3T3 fibroblasts, NMuMG clone E9 and human mesenchymal stem cells can efficiently form clusters on U-bottom microwells within 24 hours. The clusters are stable and can be efficiently harvested after culture, as demonstrated for human MSCs (figure 15).
- U-bottom microwells 3 can be used to analyse cells that are inherently resistant to aggregation, as demonstrated by the non-spheroid forming cancer cell line MDA MB231. Within 24 hours the cells form loosely packed clusters, which compact further over the subsequent days in culture, so that even stable clusters can be retrieved from the microwells 3 arrays 4 after 120 hours (figure 16 top panel).
- Mouse OP9 cells form stable clusters within 24 hours. Kept in culture in this conformation, the cells efficiently differentiate into adipocytes within three days also in the absence of exogenic adipogenic differentiation factors (Dexamethasone, IBMX and Insulin). Adipocyte clusters can be harvested from the microwell arrays at this point in time (see figure 16, bottom panel).
- U-bottom microwell arrays can be used for the planar 3D encapsulation of cells and spheroids to improve imaging quality and time consumption.
- 5% (w/v) PEG-Alexa546 U-bottom microwell arrays After polymerization, 200 ⁇ 10% PEG-Alexa488 beads were distributed on top of the microwell arrays and left to settle into the cavities. The bead filled arrays were subsequently sealed with a second layer of 5% (w/v) PEG-Alexa647, completely encapsulating the beads in one focal plane in a 3D PEG environment (see figure 17).
- microfluidic channels were generated by micromolding below the plane of microwells 3 in close proximity ( ⁇ 500 ⁇ distance) to ensure diffusion of the desired molecules within 24h.
- FITC labeled high molecular weight (2000kDa) dextran was perfused through channels beneath U-bottom microwell arrays. The dextran cannot perfuse through the hydrogel network, therefore efficiently and selectively labeling only the inside of the microfluidic channel (see figure 18).
- U-bottom microwells 3 can be functionalized with different proteins according to previously described methods (Kobel et al. 2012).
- thin films of protein are formed on a hydrophilic glass slide on which a PDMS stamp is placed to allow adsorption of the protein onto the PDMS surface.
- the protein is transferred to the hydrogel surface where it is incorporated into the hydrogel mesh through either static interactions or formation of covalent bonds.
- Alexa-647 labeled BSA to functionalize 5% (w/v) PEG-Alexa488 hydrogels (see figure 19).
- any shape U-bottom microwells 3 can be fabricated for specific applications (see figure 20). Indeed it has been shown that cells or cell aggregates function is strongly influenced by the geometry of their culture substrate. Thus, the presented microwells 3 array 4 has a high potential to answer how function is linked to geometry.
Abstract
Description
Claims
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2014/067242 WO2016103002A1 (en) | 2014-12-22 | 2014-12-22 | Devices for high-throughput aggregation and manipulation of mammalian cells |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3237597A1 true EP3237597A1 (en) | 2017-11-01 |
EP3237597B1 EP3237597B1 (en) | 2020-12-09 |
Family
ID=52424070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14830888.5A Active EP3237597B1 (en) | 2014-12-22 | 2014-12-22 | Devices for high-throughput aggregation and manipulation of mammalian cells |
Country Status (9)
Country | Link |
---|---|
US (1) | US11583860B2 (en) |
EP (1) | EP3237597B1 (en) |
JP (1) | JP7089240B2 (en) |
CN (1) | CN107257850A (en) |
CA (1) | CA2972057C (en) |
DK (1) | DK3237597T3 (en) |
ES (1) | ES2858600T3 (en) |
PT (1) | PT3237597T (en) |
WO (1) | WO2016103002A1 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011140441A2 (en) | 2010-05-06 | 2011-11-10 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
SG10202107992XA (en) * | 2014-02-27 | 2021-09-29 | Public Univ Corp Yokohama City Univ | Method for generating cell condensate for self-organization |
ES2860423T3 (en) | 2014-05-28 | 2021-10-05 | Childrens Hospital Med Ct | Methods and Systems for Converting Stem Cells to Gastric Tissues by Targeted Differentiation |
US11584916B2 (en) | 2014-10-17 | 2023-02-21 | Children's Hospital Medical Center | Method of making in vivo human small intestine organoids from pluripotent stem cells |
US11066650B2 (en) | 2016-05-05 | 2021-07-20 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
EP3296018A1 (en) | 2016-09-19 | 2018-03-21 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Organoid arrays |
JP6518985B2 (en) | 2016-09-29 | 2019-05-29 | 住友ゴム工業株式会社 | Cancer cell capture method |
JP6779483B2 (en) * | 2016-09-29 | 2020-11-04 | 住友ゴム工業株式会社 | Medical testing equipment and cell testing method |
US10941374B2 (en) | 2016-09-29 | 2021-03-09 | Sumitomo Rubber Industries, Ltd. | Medical analysis device and cell analysis method |
JP6485783B2 (en) * | 2016-09-29 | 2019-03-20 | 住友ゴム工業株式会社 | Medical inspection apparatus and cell inspection method |
EP3548507A4 (en) | 2016-12-05 | 2020-07-15 | Children's Hospital Medical Center | Colonic organoids and methods of making and using same |
JP2018108038A (en) * | 2016-12-28 | 2018-07-12 | クアーズテック株式会社 | Cell culture carrier |
CN111699244B (en) * | 2017-12-22 | 2023-11-24 | 巴斯德研究所 | Organ chip micro-fluidic device based on hydrogel |
KR20210047268A (en) * | 2018-01-23 | 2021-04-29 | 바-일란 유니버시티 | Cell culture apparatus and method |
JP7158671B2 (en) | 2018-02-14 | 2022-10-24 | 住友ゴム工業株式会社 | Specific cell capture method |
JP7109719B2 (en) | 2018-02-14 | 2022-08-01 | 住友ゴム工業株式会社 | Specific cell capture method |
FR3079524B1 (en) * | 2018-03-27 | 2020-12-18 | Univ Claude Bernard Lyon | BIOCOMPATIBLE HYDROGEL MICROWELL PLATES |
FR3081168B1 (en) * | 2018-05-21 | 2022-03-11 | Univ Bordeaux | BIOREACTOR CELL CULTURE SYSTEM |
US20210301237A1 (en) * | 2018-05-30 | 2021-09-30 | Sun Bioscience Sa | Well for cultivating biological material |
JP7348586B2 (en) * | 2019-01-18 | 2023-09-21 | 東洋製罐グループホールディングス株式会社 | Culture container, culture method, and culture device |
US11614440B2 (en) | 2019-01-24 | 2023-03-28 | Sumitomo Rubber Industries, Ltd. | Specific cell fractionating and capturing methods |
EP3750982A1 (en) * | 2019-06-10 | 2020-12-16 | UPM-Kymmene Corporation | Cell culture plate, method for preparing thereof and method for detecting a substance |
US20220275328A1 (en) * | 2020-06-25 | 2022-09-01 | Next & Bio Inc. | Method for mass proliferation of stem cells without using hydrogel |
CN114423859A (en) * | 2020-06-25 | 2022-04-29 | 株式会社下一代生物 | Method for producing induced pluripotent stem cells without using hydrogel |
US20220154140A1 (en) * | 2020-06-25 | 2022-05-19 | Next & Bio Inc. | Brain organoid manufacturing method |
US20220243172A1 (en) * | 2020-06-25 | 2022-08-04 | Next & Bio Inc. | Standard organoid production method |
CN113930337B (en) * | 2020-06-29 | 2023-03-17 | 清华大学 | Device for preparing cell clusters and construction method and application thereof |
EP4029934A1 (en) * | 2021-01-18 | 2022-07-20 | Universite De Geneve | Methods of producing cell spheroids and tool therefore |
CN113215076A (en) * | 2021-04-13 | 2021-08-06 | 华南理工大学 | Hemispherical micropore array substrate for three-dimensional cell sphere culture and preparation method thereof |
CN113667603B (en) * | 2021-08-13 | 2023-12-22 | 合肥燃音生物科技有限公司 | Liver organoid culture chip and preparation method and application thereof |
WO2023230596A1 (en) * | 2022-05-27 | 2023-11-30 | Satellite Biosciences, Inc. | Devices and methods for cell aggregation |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1664265A4 (en) * | 2003-07-21 | 2009-11-25 | Seng Entpr Ltd | Improved multiwell plate |
WO2007087402A2 (en) * | 2006-01-24 | 2007-08-02 | Brown University | Cell aggregation and encapsulation device and method |
WO2008106771A1 (en) | 2007-03-02 | 2008-09-12 | Mark Ungrin | Devices and methods for production of cell aggregates |
US9121003B2 (en) * | 2007-09-12 | 2015-09-01 | Kitakyushu Foundation For The Advancement Of Industry, Science And Technology | Cell culture instrument and cell culture method using the same |
WO2010008977A2 (en) * | 2008-07-16 | 2010-01-21 | Vance Products Incorporated D/B/A | Micro-fluidic cell manipulation and holding device |
CN101827931A (en) | 2008-08-29 | 2010-09-08 | 北京大学 | A microfluidic chip for accurately controllable cell culture |
US20100055733A1 (en) * | 2008-09-04 | 2010-03-04 | Lutolf Matthias P | Manufacture and uses of reactive microcontact printing of biomolecules on soft hydrogels |
JP6120778B2 (en) * | 2011-02-03 | 2017-04-26 | ノースイースタン ユニヴァーシティ | Methods and compositions for highly specific capture and release of biological material |
JP5487136B2 (en) * | 2011-02-14 | 2014-05-07 | 株式会社Nttドコモ | Aperiodic channel state information notification method, radio base station apparatus, user terminal |
KR101282926B1 (en) | 2011-07-28 | 2013-07-08 | 고려대학교 산학협력단 | Surface tension induced concave microwell fabrication and cell aggregation using the same |
WO2013030940A1 (en) * | 2011-08-29 | 2013-03-07 | 株式会社日立製作所 | Culturing sheet, culturing equipment material, and manufacturing method |
JP6313043B2 (en) | 2011-09-20 | 2018-04-18 | 株式会社クラレ | Method for culturing adherent cells |
JP6113999B2 (en) * | 2012-10-18 | 2017-04-12 | 株式会社クラレ | Compound screening method |
-
2014
- 2014-12-22 US US15/539,045 patent/US11583860B2/en active Active
- 2014-12-22 CA CA2972057A patent/CA2972057C/en active Active
- 2014-12-22 EP EP14830888.5A patent/EP3237597B1/en active Active
- 2014-12-22 PT PT148308885T patent/PT3237597T/en unknown
- 2014-12-22 DK DK14830888.5T patent/DK3237597T3/en active
- 2014-12-22 CN CN201480084674.2A patent/CN107257850A/en active Pending
- 2014-12-22 JP JP2017532009A patent/JP7089240B2/en active Active
- 2014-12-22 WO PCT/IB2014/067242 patent/WO2016103002A1/en active Application Filing
- 2014-12-22 ES ES14830888T patent/ES2858600T3/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2858600T3 (en) | 2021-09-30 |
CA2972057A1 (en) | 2016-06-30 |
US11583860B2 (en) | 2023-02-21 |
WO2016103002A1 (en) | 2016-06-30 |
US20180264465A1 (en) | 2018-09-20 |
DK3237597T3 (en) | 2021-03-15 |
EP3237597B1 (en) | 2020-12-09 |
CN107257850A (en) | 2017-10-17 |
JP2018504103A (en) | 2018-02-15 |
JP7089240B2 (en) | 2022-06-22 |
CA2972057C (en) | 2023-06-13 |
PT3237597T (en) | 2021-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2972057C (en) | Microstructured thin hydrogel films | |
Joseph et al. | Two-dimensional (2D) and three-dimensional (3D) cell culturing in drug discovery | |
EP3515600B1 (en) | Organoid arrays | |
Neto et al. | Patterned superhydrophobic surfaces to process and characterize biomaterials and 3D cell culture | |
Gupta et al. | Microfluidics‐based 3D cell culture models: Utility in novel drug discovery and delivery research | |
Liu et al. | A review of manufacturing capabilities of cell spheroid generation technologies and future development | |
Montanez-Sauri et al. | Microscale screening systems for 3D cellular microenvironments: platforms, advances, and challenges | |
Pampaloni et al. | Three-dimensional tissue models for drug discovery and toxicology | |
JP2020000255A (en) | Culture chamber and culture method | |
JP5676265B2 (en) | Cell storage method and cell transport method | |
WO2023020599A1 (en) | Organoid culture chip and organoid culture method | |
Peng et al. | Challenges in bio-fabrication of organoid cultures | |
Zhang et al. | High-throughput superhydrophobic microwell arrays for investigating multifactorial stem cell niches | |
Lin et al. | Transparent bioreactors based on nanoparticle-coated liquid marbles for in situ observation of suspending embryonic body formation and differentiation | |
CN113046237A (en) | Spheroid manufacturing device, spheroid recovery method and manufacturing method | |
US20220204911A1 (en) | Ferromagnetic material with remote responsive control for dynamic cell culture | |
JP2021045175A (en) | Device for manipulating mammalian cells with high collection capability | |
KR20210000552A (en) | Microwell Container for Co-Culturing of Cells, Cell Co-Culturing Method Using the Said Container, and Container-Set | |
US20240076628A1 (en) | Cell culture membrane structure, methods for producing the same, cell culture plate, cell culture apparatus comprising the cell culture membrane structure, and methods for cell cultivation by using the cell culture apparatus | |
EP4148117A1 (en) | Cell culture apparatus, methods for cell cultivation by using the same, cell culture incubator comprising the same, and uses of the cell culture apparatus | |
Vadivelu | Microbioreactors for 3-dimensional tissue | |
CN117025391A (en) | Hanging drop culture plate and hanging drop culture device | |
WO2023036909A1 (en) | Cell culture apparatus, methods for cell cultivation by using the same, cell culture incubator comprising the same, and uses of the cell culture apparatus | |
IT202100025460A1 (en) | LAB-ON-CHIP DEVICE TO STUDY CELLULAR MIGRATION IN THREE-DIMENSIONAL SYSTEMS AND RELATED METHOD OF USE | |
Todhunter | Rapid Synthesis of 3D Tissues by Chemically Programmed Assembly |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20170724 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BRANDENBERG, NATHALIE Inventor name: LUTOLF, MATTHIAS Inventor name: HOEHNEL, SYLKE |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20200617 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1343481 Country of ref document: AT Kind code of ref document: T Effective date: 20201215 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602014073245 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Ref document number: 3237597 Country of ref document: PT Date of ref document: 20210312 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20210308 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20210310 Ref country code: CH Ref legal event code: NV Representative=s name: DR. FRIEDRICH LINHART PATENTANWALT (DE, CH), CH |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210310 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210309 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210309 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20210209 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602014073245 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210409 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2858600 Country of ref document: ES Kind code of ref document: T3 Effective date: 20210930 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 |
|
26N | No opposition filed |
Effective date: 20210910 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602014073245 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210409 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201209 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20211231 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20220920 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211231 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20230124 Year of fee payment: 9 Ref country code: CH Payment date: 20221229 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20231018 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20231018 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231016 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20231016 Year of fee payment: 10 Ref country code: PT Payment date: 20231012 Year of fee payment: 10 Ref country code: IT Payment date: 20231018 Year of fee payment: 10 Ref country code: IE Payment date: 20231018 Year of fee payment: 10 Ref country code: FR Payment date: 20231016 Year of fee payment: 10 Ref country code: DE Payment date: 20231018 Year of fee payment: 10 Ref country code: AT Payment date: 20231018 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20231018 Year of fee payment: 10 |